by Salynn Boyles Contributing Writer, MedPage Today The FDA has approved AstraZeneca's biologic drug benralizumab (Fasenra) for the add-on maintenance treatment of patients age 12 years and over with severe asthma with an eosinophilic phenotype, the drugmaker announced.
FDA Approves Benralizumab for Severe Asthma
FDA Approves Benralizumab for Severe Asthma
FDA Approves Benralizumab for Severe Asthma
by Salynn Boyles Contributing Writer, MedPage Today The FDA has approved AstraZeneca's biologic drug benralizumab (Fasenra) for the add-on maintenance treatment of patients age 12 years and over with severe asthma with an eosinophilic phenotype, the drugmaker announced.